SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lemercier Jean-Luc M

(Last)

(First)

(Middle)

ONE EDWARDS WAY

(Street)

IRVINE

92614

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2017

3. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CVP, EMEA, Canada, Latin Amer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	38,665.4191⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Acquire)	02/20/2015⁽²⁾	02/19/2021	Common Stock	5,002	$34.05	D
Employee Stock Option (Right to Acquire)	05/14/2014⁽²⁾	05/13/2020	Common Stock	13,880	$35.785	D
Employee Stock Option (Right to Acquire)	05/08/2015⁽²⁾	05/07/2021	Common Stock	17,360	$41.94	D
Employee Stock Option (Right to Acquire)	05/09/2013⁽²⁾	05/08/2019	Common Stock	12,560	$42.725	D
Employee Stock Option (Right to Acquire)	05/12/2012⁽²⁾	05/11/2018	Common Stock	16,900	$44.615	D
Employee Stock Option (Right to Acquire)	05/14/2016⁽²⁾	05/13/2022	Common Stock	11,660	$65.28	D
Employee Stock Option (Right to Acquire)	05/12/2017⁽²⁾	05/11/2023	Common Stock	6,640	$105.59	D
Employee Stock Option (Right to Acquire)	05/11/2018⁽²⁾	05/10/2024	Common Stock	14,400	$110.25	D
Performance Rights	05/11/2020⁽³⁾	⁽³⁾	Common Stock	2,050⁽³⁾	⁽³⁾	D

Explanation of Responses:

1. This amount includes the following four grants of restricted stock units (RSUs) made under the Edwards Lifesciences Corporation Long-Term Stock Incentive Program each of which vests 50% on the thrid anniversary of the grant date and 50% on the fourth anniversary of the grant date: (i) 2,150 RSUs on May 8, 2014, (ii) 1,380 RSUs on May 14, 2015, (iii) 850 RSUs on 5/12/2016, and (iv) 1,625 on 5/11/2017.

2. These options were granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program with vesting commencing one year after the grant date in four equal annual installments.

3. Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

Remarks:

lemercierpoa.txt

	Ifigenia Protopappas, Attorney-in-fact	07/05/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.